News articles about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.592964280808 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Zogenix (NASDAQ ZGNX) opened at $34.10 on Thursday. Zogenix has a one year low of $7.70 and a one year high of $42.60. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.71 and a current ratio of 2.71.

A number of research firms have issued reports on ZGNX. Zacks Investment Research downgraded Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. JMP Securities began coverage on Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target for the company. BidaskClub raised Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Leerink Swann reissued an “outperform” rating and set a $50.00 price target (up previously from $20.00) on shares of Zogenix in a research report on Monday, October 2nd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $42.67.

In related news, major shareholder Life Sciences Maste Perceptive acquired 300,000 shares of Zogenix stock in a transaction on Tuesday, October 3rd. The shares were bought at an average price of $37.50 per share, for a total transaction of $11,250,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Stock Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related stocks with our FREE daily email newsletter.